Maarten L. Janmaat

Maarten L. Janmaat

Auto-generated profile, based on publicly available information

Maarten L. Janmaat

Genmab, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2019 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
ALAran F. Labrijn
Aran F. Labrijn
MJMaarten L. Janmaat
Maarten L. Janmaat
JRJanice M. Reichert
Janice M. Reichert
PPPaul W. H. I. Parren
Paul W. H. I. Parren

10 February 2016 in Immunological Reviews
Verified
Journal Article
Open access
PDF file
NDNiels W. C. J. van de Donk
Niels W. C. J. van de Donk
MJMaarten L. Janmaat
Maarten L. Janmaat
TMTuna Mutis
Tuna Mutis
JBJeroen J. Lammerts van Bueren
Jeroen J. Lammerts van Bueren
TATahamtan Ahmadi
Tahamtan Ahmadi
PPPaul W. H. I. Parren
Paul W. H. I. Parren
Summary: CD38 is a multifunctional cell surface protein that has receptor as well as enzyme functions. The protein is generally expressed at low levels on various hematological and solid tissues, while plasma cells express particularly high levels of CD38. The protein is also expressed in a subset of hematological tumors, and shows especially broad and high expression levels in plasma cell tumors such as multiple myeloma (MM). Together, this triggered the development of various therapeutic CD38 antibodies, including daratumumab, isatuximab, and MOR202. Daratumumab binds a unique CD38 epitope and showed strong anti‐tumor activity in preclinical models. The antibody engages diverse mechanisms of action, including complement‐dependent cytotoxicity, antibody‐dependent cellular cytotoxicity, antibody‐dependent cellular phagocytosis, programmed cell death, modulation of enzymatic activity, and immunomodulatory activity. CD38‐targeting antibodies have a favorable toxicity profile in patients, and early clinical data show a marked activity in MM, while studies in other hematological malignancies are ongoing. Daratumumab has single agent activity and a limited toxicity profile, allowing favorable combination therapies with existing as well as emerging therapies, which are currently evaluated in the clinic. Finally, CD38 antibodies may have a role in the treatment of diseases beyond hematological malignancies, including solid tumors and antibody‐mediated autoimmune diseases.

15 January 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JBJulia Boshuizen
Julia Boshuizen
LKLouise A Koopman
Louise A Koopman
OKOscar Krijgsman
Oscar Krijgsman
ASAida Shahrabi
Aida Shahrabi
EHElke Gresnigt– van Den Heuvel
Elke Gresnigt– van Den Heuvel
PPPaul W H I Parren
Paul W H I Parren

1 April 2006 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MJMaarten L. Janmaat
Maarten L. Janmaat
MGMariëlle I. Gallegos-Ruiz
Mariëlle I. Gallegos-Ruiz
JRJose Antonio Rodriguez
Jose Antonio Rodriguez
GMGerrit A. Meijer
Gerrit A. Meijer
WVWalter L. Vervenne
Walter L. Vervenne
GGGiuseppe Giaccone
Giuseppe Giaccone
Purpose: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib was assessed in a phase II study in patients with advanced esophageal cancer. Several biologic features were investigated as potential markers of gefitinib activity. Patients and Methods: Patients with advanced esophageal cancer, who had failed one line of prior chemotherapy, were administered gefitinib 500 mg/d. Response was evaluated every 8 weeks. Tumor material obtained before gefitinib treatment was investigated for gene mutations in EGFR, k-ras, and PIK3CA; protein expression levels of EGFR, p-Akt, and p-Erk; and EGFR gene amplification. Results: Of the 36 enrolled patients, one (2.8%) achieved a partial response, 10 (27.8%) had stable disease, 17 (47.2%) experienced progression on treatment, and eight (22.2%) were not assessable for response. The progression-free survival time was 59 days, and the median overall survival time was 164 days. Although EGFR or PIK3CA mutations were absent, k-ras mutations were found in two patients with progressive disease. High EGFR gene copy number was identified in two patients experiencing partial response or progressive disease. A higher disease control rate (response plus stable disease) was observed in females (P = .038) and in patients with squamous cell carcinoma (SCC; P = .013) or high EGFR expression (P = .002). Conclusion: Gefitinib has a modest activity in second-line treatment of advanced esophageal cancer. However, the patient outcome was significantly better in female patients and in patients demonstrating high EGFR expression or SCC histology. The selection of esophageal cancer patients for future studies with EGFR-TKIs based on the level of EGFR expression in their tumors or SCC histology should be considered.

26 October 2005 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MJMaarten L. Janmaat
Maarten L. Janmaat
JRJose Antonio Rodriguez
Jose Antonio Rodriguez
MGMariëlle Gallegos‐Ruiz
Mariëlle Gallegos‐Ruiz
Frank A. E. KruytFrank A. E. Kruyt
Frank A. E. Kruyt
GGGiuseppe Giaccone
Giuseppe Giaccone
In this study, we have characterized a panel of NSCLC cell lines with differential sensitivity to gefitinib for activating mutations in egfr, pik3ca, and k‐ras, and basal protein expression levels of PTEN. The egfr mutant NSCLC cell line H1650 as well as the egfr wild type cell lines H292 and A431 were highly sensitive to gefitinib treatment, indicating that other factors determine gefitinib‐sensitivity in egfr wild type cells. Activating k‐ras mutations were specifically detected in gefitinib‐resistant cells, suggesting that the occurrence of k‐ras mutations is correlated with resistance to EGFR antagonists. No pik3ca mutations were detected within the panel of cell lines, and PTEN protein expression levels did not correlate with gefitinib sensitivity. Gefitinib effectively blocked Akt and Erk phosphorylation in two gefitinib‐sensitive NSCLC cell lines, further supporting our previous findings that persistent activity of the PI3K/Akt and/or Ras/Erk pathways is associated with gefitinib‐resistance of NSCLC cell lines. Gefitinib‐resistant NSCLC cell lines, showing EGFR‐independent activity of the PI3K/Akt or Ras/Erk pathways, were treated with gefitinib in combination with specific inhibitors of mTOR, P13K, Ras, and MEK. Additive cytotoxicity was observed in A549 cells co‐treated with gefitinib and the MEK inhibitor U0126 or the farnesyl transferase inhibitor SCH66336 and in H460 cells treated with gefitinib and the PI3K inhibitor LY294002, but not in H460 cells treated with gefitinib and rapamycin. These data suggest that combination treatment of NSCLC cells with gefitinib and specific inhibitors of the PI3K/Akt and Ras/Erk pathways may provide a successful strategy.

1 August 2005 in Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
MJMaarten L. Janmaat
Maarten L. Janmaat
JRJose Antonio Rodriguez
Jose Antonio Rodriguez
JJJosé Jimeno
José Jimeno
Frank A. E. KruytFrank A. E. Kruyt
Frank A. E. Kruyt
GGGiuseppe Giaccone
Giuseppe Giaccone
Kahalalide F (KF) is a novel marine-derived antitumor agent that is currently undergoing phase II clinical trials. The mechanism of action of KF is not well understood. In line with previous reports, we show that KF caused rapid and potent cytotoxicity in the breast cancer cell lines SKBR3 and BT474, characterized by cytoplasmic swelling and DNA clumping. Several markers of caspase-dependent apoptosis, such as phosphatidyl-serine externalization, cytochrome c release, and caspase-3 and poly-(ADP-ribose) polymerase cleavage were negative after KF exposure. Inhibitors of caspases or cathepsins failed to protect against KF cytotoxicity. Altogether, these data indicate that KF-induced cell death is a necrosis-like process. The sensitivity to KF in a panel of human tumor cell lines derived from breast (SKBR3, BT474, and MCF7), vulval (A431), non–small-cell lung (H460, A549, SW1573, and H292), and hepatic (Skhep1, HepG2, and Hep3B) carcinomas positively correlated with ErbB3 (HER3) protein levels. A KF-resistant subline of colon carcinoma cells, HT29/KF, expressed significantly reduced levels of all ErbB receptors, but short-term KF exposure of sensitive cell lines such as SKBR3 selectively induced down-regulation of ErbB3. On the other hand, stable transfection of an ErbB3-expressing plasmid increased the KF sensitivity of H460 cells, the most resistant cell line in our panel. Finally, we found that KF efficiently inhibited the phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway in sensitive cell lines and that ectopic expression of a constitutively active Akt mutant reduced KF cytotoxicity in this cell line. In summary, our results identify ErbB3 and the downstream PI3K-Akt pathway as important determinants of the cytotoxic activity of KF in vitro.